MDxHealth Toekomstige groei
Future criteriumcontroles 1/6
MDxHealth is forecast to grow earnings and revenue by 36.1% and 12.3% per annum respectively while EPS is expected to grow by 42.3% per annum.
Belangrijke informatie
42.3%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.1% |
| Inkomstengroei | 12.3% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 15 Oct 2024 |
Recente toekomstige groei-updates
Winst- en omzetgroeiprognoses
NasdaqCM:MDXH - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|
| 12/31/2026 | 108 | -16 | 6 | 8 | 3 |
| 12/31/2025 | 97 | -22 | -7 | -3 | 5 |
| 12/31/2024 | 84 | -35 | -20 | -16 | 5 |
| 6/30/2024 | 81 | -41 | -25 | -21 | N/A |
| 3/31/2024 | 75 | -40 | -27 | -23 | N/A |
| 12/31/2023 | 70 | -43 | -27 | -21 | N/A |
| 9/30/2023 | 64 | -45 | -30 | -24 | N/A |
| 6/30/2023 | 55 | -48 | -35 | -29 | N/A |
| 3/31/2023 | 46 | -47 | -34 | -30 | N/A |
| 12/31/2022 | 37 | -44 | -38 | -34 | N/A |
| 9/30/2022 | 30 | -40 | -32 | -30 | N/A |
| 6/30/2022 | 25 | -34 | -28 | -26 | N/A |
| 3/31/2022 | 23 | -31 | N/A | N/A | N/A |
| 12/31/2021 | 22 | -29 | -23 | -23 | N/A |
| 9/30/2021 | 21 | -28 | -22 | -21 | N/A |
| 6/30/2021 | 19 | -28 | -21 | -21 | N/A |
| 3/31/2021 | 19 | -28 | N/A | N/A | N/A |
| 12/31/2020 | 18 | -29 | -21 | -20 | N/A |
| 9/30/2020 | 15 | -36 | -20 | -20 | N/A |
| 6/30/2020 | 11 | -43 | -20 | -20 | N/A |
| 3/31/2020 | 11 | -43 | -21 | -21 | N/A |
| 12/31/2019 | 12 | -43 | -22 | -22 | N/A |
| 9/30/2019 | 17 | -37 | -25 | -25 | N/A |
| 6/30/2019 | 22 | -31 | -28 | -27 | N/A |
| 3/31/2019 | 25 | -32 | -29 | -28 | N/A |
| 12/31/2018 | 28 | -32 | -30 | -29 | N/A |
| 9/30/2018 | 31 | -30 | -30 | -28 | N/A |
| 6/30/2018 | 33 | -28 | -31 | -27 | N/A |
| 3/31/2018 | 37 | -20 | N/A | -19 | N/A |
| 12/31/2017 | 41 | -12 | N/A | -10 | N/A |
| 9/30/2017 | 41 | -9 | N/A | -8 | N/A |
| 6/30/2017 | 41 | -5 | N/A | -5 | N/A |
| 3/31/2017 | 36 | -9 | N/A | -11 | N/A |
| 12/31/2016 | 30 | -13 | N/A | -17 | N/A |
| 9/30/2016 | 26 | -15 | N/A | -17 | N/A |
| 6/30/2016 | 23 | -17 | N/A | -16 | N/A |
| 3/31/2016 | 20 | -16 | N/A | -15 | N/A |
| 12/31/2015 | 18 | -14 | N/A | -14 | N/A |
| 9/30/2015 | 16 | -14 | N/A | -15 | N/A |
| 6/30/2015 | 15 | -13 | N/A | -15 | N/A |
| 3/31/2015 | 13 | -14 | N/A | -17 | N/A |
| 12/31/2014 | 12 | -15 | N/A | -19 | N/A |
| 9/30/2014 | 10 | -16 | N/A | -19 | N/A |
| 6/30/2014 | 8 | -16 | N/A | -19 | N/A |
| 3/31/2014 | 8 | -16 | N/A | -17 | N/A |
| 12/31/2013 | 8 | -16 | N/A | -14 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: MDXH is forecast to remain unprofitable over the next 3 years.
Winst versus markt: MDXH is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: MDXH is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: MDXH's revenue (12.3% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: MDXH's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if MDXH's Return on Equity is forecast to be high in 3 years time